Skip to content
Triangle logo TriangleGet started
← Study library

NCT02863991 · REGISTRY CONDITION SEARCH

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
TERMINATED
Registry last update
2024-07-03

This was a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone in adults with relapsed/refractory multiple myeloma. The primary objective of this study was to evaluate the antitumor efficacy of ONC201. Note: This study was completed by predecessor company, Oncoceutics, Inc.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Response of Participants at Last On-study Visit (End of Treatment/Follow-up)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: A patient had to meet all of the following criteria to be eligible to participate in the study: 1. Must have been refractory to, or not a candidate for, established therapy known to provide clinical benefit for their malignancy. 2. Had measurable disease M protein component in serum (at least 0.5 g/dL) and/or urine (if present) (≥0.2 g excreted in a 24 hour collection sample), or serum free light chain level ≥10 mg/dL, provided the serum free light chain ratio was abnormal. 3. Was able to swallow and retain oral medication. 4. Had all previous therapies for cancer, including radiotherapy, major surgery and investigational therapies discontinued for ≥14 days (≥28 days for mitomycin C or nitrosoureas) before study entry, and had all acute effects of any prior therapy resolved to baseline severity or Grade ≤1 Common Terminology Criteria for Adverse Events (CTCAE v4.03), except alopecia or parameters defined in this eligibility list. 5. Were aged ≥18 years. 6. Had an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1. 7. Had adequate organ and marrow function as defined below: 1. Absolute neutrophil count: ≥1,000/mm3 without growth factor use ≤7 days prior to treatment (cycle 1 day 1, C1D1) 2. Platelets: ≥75,000/mm3 without platelet transfusion ≤3 days prior to C1D1 3. Hemoglobin: 8.0 mg/dL without red blood cell transfusion ≤3 days prior to C1D1 4. Total serum bilirubin: ≤1.5 X upper limit of normal (ULN) 5. Aspartate aminotransferase (AST) (SGOT)/alanine aminotransferase (ALT) (SGPT): ≤2 X ULN; ≤ 5 X ULN if liver dysfunction was felt to be secondary to tumor burden 6. Serum creatinine: ≤1.5 X ULN (OR creatinine clearance ≥30 mL/min/1.73 m2) 7. Serum or urine pregnancy test (for females of childbearing potential) negative ≤7days of starting treatment 8. Had the ability to understand and the willingness to sign a written informed consent document and comply with the study scheduled visits, treatment plans, laboratory tests and other procedures. 9. Female patients must have been surgically sterile or be postmenopausal, or must have agreed to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. Male patients must have been surgically sterile or must have agreed to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. The decision of effective contraception was based on the judgment of the principal investigator or a designated associate. Exclusion Criteria: A potential patient who met any of the following criteria was ineligible to participate in the study: 1. Had active inflammatory gastrointestinal disease, chronic diarrhea (unless related to underlying malignancy or prior related treatment) or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within 6 months prior to study enrollment. Gastroesophageal reflux disease under treatment with proton pump inhibitors was allowed. 2. Was pregnant or breast feeding. 3. Was undergoing current active treatment in another clinical study. 4. Had active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV) 5. Had known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness that was not well controlled. 6. Had active or prior plasma cell leukemia (defined as either 20% of peripheral white blood cell count \[WBC\] comprised of plasma/CD138+ cells or an absolute count of 2x10\^9/L). 7. Had solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia. 8. Had serum calcium (corrected for albumin) ≥12 mg/dL 9. Had any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism. 10. Had other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may have increased the risk associated with study participation or study drug administration, or may have interfered with the interpretation of study results, or in the judgment of the investigator would have made the patient inappropriate for entry into the study.
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients received 375 mg ONC201 once every week in combination with dexamethasone.
    intervention Names
    1. Drug: ONC201
    2. Drug: Dexamethasone
    label
    375 mg ONC201
    type
    EXPERIMENTAL
  2. description
    Patients received 625 mg ONC201 once every week in combination with dexamethasone.
    intervention Names
    1. Drug: ONC201
    2. Drug: Dexamethasone
    label
    625 mg ONC201
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. 375 mg ONC201
    2. 625 mg ONC201
    description
    375 mg or 625 mg ONC201
    name
    ONC201
    type
    DRUG
  2. arm Group Labels
    1. 375 mg ONC201
    2. 625 mg ONC201
    description
    20 mg dexamethasone
    name
    Dexamethasone
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
17
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Assessments of response were made using the International Myeloma Working Group (IMWG) response criteria and were assessed by magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET)/CT scans (when applicable). Per IMWG response criteria, objective response could be defined as follows: complete response (CR), disappearance of any soft tissue plasmacytomas; partial response (PR), a \>50% reduction in size of soft tissue plasmacytomas; progressive disease (PD), definite development of new or a definite increase of size of existing soft tissue plasmacytomas; and stable disease (SD), not meeting criteria for CR, PR, or PD.
    measure
    Response of Participants at Last On-study Visit (End of Treatment/Follow-up)
    time Frame
    The response assessment data reported was conducted at the last on-study visit (end of treatment/follow-up), up to a maximum of 7 months following treatment initiation.
Full study description
brief Summary
This was a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone in adults with relapsed/refractory multiple myeloma. The primary objective of this study was to evaluate the antitumor efficacy of ONC201. Note: This study was completed by predecessor company, Oncoceutics, Inc.
detailed Description
In Phase 1 of the study, patients were to receive 375 or 625 mg ONC201 once every week in combination with dexamethasone using a 3+3 dose escalation design to evaluate up to 625 mg ONC201 weekly with 20 mg dexamethasone. In Phase 2 of the study, patients were to receive 625 mg ONC201 once every week. Dexamethasone was to be administered at a dose determined in Phase 1. A treatment cycle was defined as 3 weeks. The dose-limiting toxicity window was defined as the first 3 weeks of treatment (i.e., 1 cycle). Patients may have continued treatment with ONC201 until disease progression, occurrence of an unacceptable adverse event, intercurrent illness or changes in the patient's condition rendered the patient unacceptable to continue, patient decision to withdraw from the study, or discontinuation of the study by the Sponsor. Assessments of tumor response were conducted using the International Myeloma Working Group response criteria. Safety was assessed through the reporting of adverse events, measurement of vital signs, electrocardiograms, and clinical laboratory results. Before the study was terminated, a total of 17 patients were enrolled and treated with ONC201: 2 patients received 375 mg ONC201 and 15 patients received 625 mg ONC201.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-78809debfb486572cf60
      requested nct id
      NCT02863991
      primary nct id
      NCT02863991
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      22a054713b4544be30ffeb76fa0dc6465bdc621ed5b3eb739a3b9f74224af7fc
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-78809debfb486572cf60
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02863991
      occurrences
      1. context exact
        NCT02863991
        end
        11
        exact text
        NCT02863991
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/145/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      1a4f115397ce9ae60cb2a5357dafef70a0ae944b5d193292d2945cf3617db6b2

    Preserved source evidence · Not medical advice